About this Research Topic
We are happy to launch a second volume considering the success of the first Volume "Advances in gene therapy, immunotherapy, and 3D bioprinting".
Nanotechnology has sparked a rapidly growing interest in cancer nanomedicine, promising to solve several issues associated with conventional therapeutic agents, including their poor water solubility, lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Biomedical nanotechnology has been investigated as a tool in cancer therapy based on genomic, epigenomic, and proteomic profiles. These approaches are enabling a successful delivery with precision, protecting the cargo from degradation, releasing it at the tumor site, and improving the selectivity to cancer treatment. In addition, advances in biomaterials and delivery systems also offer several tools to tailor cancer immunotherapy by improving antigenic presentation and consequently generating a robust antitumor immune response. 3D bioprinting, as an in vitro model capable of replicating native cancer tissue behaviors, can significantly improve the understanding of cancer biology and help guide the development of more effective treatments, representing an additional tool for cancer therapies.
This second volume of the Research Topic still aims to fully cover the development of nanosystems as efficient tools for the therapeutic delivery to cancer tissues. The advances in nanotechnology and bioengineering have identified many genomic, epigenomic, and proteomic targets. This issue aims to focus anticancer therapeutic strategies based on the specific and targeted delivery of drugs, peptides, and proteins, DNA, and RNA vectors. Thus, it will also contain current applications of nanomaterials in cancer immunotherapy, including adoptive cell therapy (ACT) and therapeutic cancer vaccines, and shed light on future directions of nanotechnology-based cancer immunotherapy. Moreover, this issue aims to present a 3D bioprinting strategy to build functional cancer tissue models and identify the advantages and disadvantages of this technology as a model for cancer treatment.
In this Research Topic, we welcome original articles as well as review articles that contribute to our understanding of the nanobiotechnology in cancer therapies through combining biotechnologies in genetic, epigenetic, proteomic, and immunotherapy and 3D- bioprinting with current nanotechnologies, including:
• Nanomaterials engineered for cancer chemotherapy anticancer vaccine delivery.
• Nanobiotechnology for treatment of metastatic cancer
• Nanotechnology-based delivery systems for photodynamic/photothermal therapy of cancer
• A DNA-based nanocarrier for efficient cancer genotherapy.
• Nanotechnology-based RNA (mRNA, miRNA, siRNA, and shRNA) delivery strategies for cancer therapy.
• Nanotechnology platform to improve proteomic evaluation to cancer therapy.
• Epigenetics in cancer therapy and nanomedicine
• Nanotechnology for nucleic acid delivery to cancer immunotherapy.
• 3D cellular bioprinting to create tissue models that replicate the tumor microenvironment.
• 3D cellular bioprinting for the analysis of the screening, action, and resistance of antitumor drug
• 3D printing technology combined with improved electrospinning or solution blow spinning technology for cancer drug delivery.
• The hydrogel and hydrogels bio links in 3D bioprinting as a technology cancer treatment model.
• 2D and 3D Polymers Platforms for Cancer disease models
Keywords: Cancer Therapy, Nanotechnology, Gene Therapy, Immunotherapy, 3D Bioprinting
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.